Everlinq Reports Successful New Approach to Vascular Access

The everlinQ^TM System forms an HD access with radiofrequency energy at sites not traditionally used by surgeons. The system has CE Mark approval, but is not yet available in the U.S.

Read the full article » | Posted 12-10-2015

Related Articles

• The Lancet Digital Health published results of Humacyte’s Phase III clinical trial of its V007 acellular tissue engineered vessel (ATEV) HD access Posted 09-18-2026
• Humacyte, Inc. announced Robert J. Kossman, MD, FACP, FASN and Prabir Roy-Chaudhury, MD, PhD, FASN have joined the company as advisors. Posted 08-21-2026
• Byonyks on the Move: X-2 and X-3 APD Devices in Development Posted 07-16-2026
• Dr. Ben Reynolds and the Virtual Reality Kidney Dialysis Training Project Posted 06-17-2026